Inclusion Criteria:

• Age > 18 years
• Patients with inoperable locoregional or advanced NSCLC irrespective of histological subtype where chemotherapeutical treatment options are depleted.
• Histologically or cytologically confirmed diagnosis
• Access to histological tumour material from the patient
• Performance <2 (Eastern Cooperative Oncology Group (ECOG) performance scale)
• Expected remaining lifetime of min. 12 weeks
• Inclusion shall take place at least 4 weeks after the latest dosage of chemotherapy.
• Inclusion shall take place at least 4 weeks after the latest radiation therapy.
• Inclusion shall take place at least 1 week after latest treatment with immunosuppressing drugs (incl. Prednisolone).
• Patients who have recovered (CTC<1) from the acute toxicity in connection with any other previous treatment.
• Granulocytes ≥1.5 x 109/L and thrombocytes >100 x 109/L
• Serum bilirubin ≤1.5 x ULN
• AST and/or ALT ≤2 x ULN (or ≤5 x ULN if hepatic metastases)
• Liver and kidneys <2 x ULN – however, LDH can be increased without restrictions.
• Serum creatinine ≤1.5 x ULN or creatinine clearance ≥60 ml/min.
• Women of childbearing potential must use safe contraception.
• At least one measurable parameter after RECIST criteria
• Signed informed consent form after oral as well as written information.
• The patient must be willing to use the adjuvants (celecoxib 200 mg/day, Iron C 100 mg/day, Aldara cream 5% and IL-2) from the time of the first vaccination and to the completion of the study unless side effects will necessitate withdrawal.

Exclusion Criteria:

• Malign disease during the latest five years.
• Any form of unstable systemic disease, including acute infection and level 4 hypertension, unstable angina, cardiac disease as well as liver and kidney diseases and metabolic diseases.
• Patients who can not take oral drugs or have previously had surgery affecting food uptake.
• Patients with present or previous ulcus disease or dyspeptic genes within three months. However, patients taking antacids, H2 blockers or PPI can be included
• Serious medical disease, e.g. severe asthma, poorly controlled cardiovascular disease
• Acute/chronic infection of HIV, hepatitis, tuberculosis among other things
• Serious allergy or previous anaphylactic reactions
• Autoimmune diseases (e.g. autoimmune neutropenia/thrombocytopenia or haemolytic anaemia, systemic lupus erythematosus, Sjøgren’s disease, sclerodermia, myasthenia gravis, Goodpasture’s syndrome, Addison’s disease, Hashimoto’s thyroiditis, active Graves’ disease)
• Pregnant and lactating women
• Mental diseases which can affect the patients’ compliance of the study according to the opinion of the investigator.
• Known hypersensitivity to the substances of the adjuvants (celecoxib, Iron C, Aldara cream, “patches”, IL-2).
• Concomitant treatment of immunosuppressing drugs (incl. Prednisolone)
• Concomitant treatment with other experimental substances
• Concomitant, other systemic anticancer treatment.